A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

NCT01028222 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Nilotinib
DRUG: DTIC

Sponsor

Novartis Pharmaceuticals